187 related articles for article (PubMed ID: 18349319)
1. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3.
Chang YC; Chen TC; Lee CT; Yang CY; Wang HW; Wang CC; Hsieh SL
Blood; 2008 May; 111(10):5054-63. PubMed ID: 18349319
[TBL] [Abstract][Full Text] [Related]
2. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages.
Tai SK; Chang HC; Lan KL; Lee CT; Yang CY; Chen NJ; Chou TY; Tarng DC; Hsieh SL
J Immunol; 2012 Mar; 188(5):2464-71. PubMed ID: 22287720
[TBL] [Abstract][Full Text] [Related]
3.
Sengupta S; Naz S; Das I; Ahad A; Padhi A; Naik SK; Ganguli G; Pattanaik KP; Raghav SK; Nandicoori VK; Sonawane A
J Biol Chem; 2017 Apr; 292(17):6855-6868. PubMed ID: 28209712
[No Abstract] [Full Text] [Related]
4. The arginine methyltransferase PRMT5 regulates CIITA-dependent MHC II transcription.
Fan Z; Kong X; Xia J; Wu X; Li H; Xu H; Fang M; Xu Y
Biochim Biophys Acta; 2016 May; 1859(5):687-96. PubMed ID: 26972221
[TBL] [Abstract][Full Text] [Related]
5. Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter.
Choi YE; Yu HN; Yoon CH; Bae YS
Eur J Immunol; 2009 Mar; 39(3):858-68. PubMed ID: 19224634
[TBL] [Abstract][Full Text] [Related]
6. Decoy receptor 3 regulates the expression of various genes in rheumatoid arthritis synovial fibroblasts.
Fukuda K; Miura Y; Maeda T; Takahashi M; Hayashi S; Kurosaka M
Int J Mol Med; 2013 Oct; 32(4):910-6. PubMed ID: 23912906
[TBL] [Abstract][Full Text] [Related]
7. FoxO1 is a regulator of MHC-II expression and anti-tumor effect of tumor-associated macrophages.
Yang JB; Zhao ZB; Liu QZ; Hu TD; Long J; Yan K; Lian ZX
Oncogene; 2018 Mar; 37(9):1192-1204. PubMed ID: 29238041
[TBL] [Abstract][Full Text] [Related]
8. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.
Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S
J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide inhibits INFgamma-induced increases in CIITA mRNA abundance and activation of CIITA dependent genes--class II MHC, Ii and H-2M. Class II TransActivator.
Kielar ML; Sicher SC; Penfield JG; Jeyarajah DR; Lu CY
Inflammation; 2000 Oct; 24(5):431-45. PubMed ID: 10921507
[TBL] [Abstract][Full Text] [Related]
10. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
11. IFN-gamma regulation of class II transactivator promoter IV in macrophages and microglia: involvement of the suppressors of cytokine signaling-1 protein.
O'Keefe GM; Nguyen VT; Ping Tang LL; Benveniste EN
J Immunol; 2001 Feb; 166(4):2260-9. PubMed ID: 11160280
[TBL] [Abstract][Full Text] [Related]
12. Differential selectivity of CIITA promoter activation by IFN-gamma and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-alpha.
Nikcevich KM; Piskurich JF; Hellendall RP; Wang Y; Ting JP
J Neuroimmunol; 1999 Oct; 99(2):195-204. PubMed ID: 10505975
[TBL] [Abstract][Full Text] [Related]
13. HLA-dependent tumour development: a role for tumour associate macrophages?
Marchesi M; Andersson E; Villabona L; Seliger B; Lundqvist A; Kiessling R; Masucci GV
J Transl Med; 2013 Oct; 11():247. PubMed ID: 24093459
[TBL] [Abstract][Full Text] [Related]
14. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas.
Kanaseki T; Ikeda H; Takamura Y; Toyota M; Hirohashi Y; Tokino T; Himi T; Sato N
J Immunol; 2003 May; 170(10):4980-5. PubMed ID: 12734341
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus transcription activator Rta upregulates decoy receptor 3 expression by binding to its promoter.
Ho CH; Hsu CF; Fong PF; Tai SK; Hsieh SL; Chen CJ
J Virol; 2007 May; 81(9):4837-47. PubMed ID: 17301127
[TBL] [Abstract][Full Text] [Related]
17. Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions.
Hsieh SL; Lin WW
J Biomed Sci; 2017 Jun; 24(1):39. PubMed ID: 28629361
[TBL] [Abstract][Full Text] [Related]
18. Capsaicin inhibits IFN-gamma-induced MHC class II expression by suppressing transcription of class II transactivator gene in murine peritoneal macrophages.
Mahmoud ME; Nikami H; Shiina T; Takewaki T; Shimizu Y
Int Immunopharmacol; 2010 Jan; 10(1):86-90. PubMed ID: 19825429
[TBL] [Abstract][Full Text] [Related]
19. Deregulated MHC class II transactivator expression leads to a strong Th2 bias in CD4+ T lymphocytes.
Otten LA; Tacchini-Cottier F; Lohoff M; Annunziato F; Cosmi L; Scarpellino L; Louis J; Steimle V; Reith W; Acha-Orbea H
J Immunol; 2003 Feb; 170(3):1150-7. PubMed ID: 12538670
[TBL] [Abstract][Full Text] [Related]
20. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells.
Zhang Y; Li D; Zhao X; Song S; Zhang L; Zhu D; Wang Z; Chen X; Zhou J
Biochem Biophys Res Commun; 2015 Aug; 463(4):1144-51. PubMed ID: 26102031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
